1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2020, provides an overview of the Female Contraception (Women's Health) pipeline landscape.
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 3, 13 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.
Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Female Contraception - Overview
- Female Contraception - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Female Contraception - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Contraception - Companies Involved in Therapeutics Development
- Adare Pharmaceuticals Inc
- Agile Therapeutics Inc
- Dare Bioscience Inc
- Evestra Inc
- Exeltis Pharmaceuticals Holding SL
- Hervana Ltd
- Luye Pharma Group Ltd
- MedinCell SA
- Micron Biomedical Inc
- Mithra Pharmaceuticals SA
- Mucommune LLC
- Navad Life Sciences Pte Ltd
- Orion Biotechnology Canada Ltd
- Ovastasis LLC
- Teva Pharmaceutical Industries Ltd
- Viramal Ltd
- Yaso Therapeutics Inc
- YourChoice Therapeutics Inc
- Female Contraception - Drug Profiles
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- Product Description
- Mechanism Of Action
- R&D Progress
- AG-200 ER - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AG-200 SP - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Female Contraception - Dormant Projects
- Female Contraception - Discontinued Products
- Female Contraception - Product Development Milestones
- Featured News & Press Releases
- May 20, 2020: Mithra and Searchlight Pharma announce filing of New Drug Submission for Estelle in Canada
- Apr 22, 2020: MedinCell launches regulatory development of mdc-WWM program
- Apr 16, 2020: Mayne Pharma submits New Drug Application for E4/DRSP to the FDA
- Mar 03, 2020: Mithra receives acceptance of marketing authorization application (MAA) to market Estelle in Belgium and Luxembourg
- Feb 27, 2020: EMA accepts Richter’s Marketing Authorization Application for Estelle, a novel combined oral contraceptive
- Feb 10, 2020: Mithra’s E4-based product Estelle to benefit from positive ruling on Patent Income Deduction
- Dec 05, 2019: Once-A-month oral contraceptive pill in development
- Nov 28, 2019: Medincell receives $19 million grant for Its mdc-WWM program
- Oct 22, 2019: Mithra announces publication of Estelle abstracts in connection with the 13th Annual Meeting of the European Society of Gynecology
- Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology
- Aug 08, 2019: Mithra obtains crucial additional Estelle patent in Japan
- Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary nationwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results
- Apr 02, 2019: Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle
- Feb 13, 2019: Mithra successfully produces its first commercial batch of Myring for Europe
- Jan 30, 2019: Mithra announces positive top-line results of Estelle phase III oral contraceptive study in U.S/Canada
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Female Contraception, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Female Contraception - Pipeline by Adare Pharmaceuticals Inc, H1 2020
- Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2020
- Female Contraception - Pipeline by Dare Bioscience Inc, H1 2020
- Female Contraception - Pipeline by Evestra Inc, H1 2020
- Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, H1 2020
- Female Contraception - Pipeline by Hervana Ltd, H1 2020
- Female Contraception - Pipeline by Luye Pharma Group Ltd, H1 2020
- Female Contraception - Pipeline by MedinCell SA, H1 2020
- Female Contraception - Pipeline by Micron Biomedical Inc, H1 2020
- Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2020
- Female Contraception - Pipeline by Mucommune LLC, H1 2020
- Female Contraception - Pipeline by Navad Life Sciences Pte Ltd, H1 2020
- Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, H1 2020
- Female Contraception - Pipeline by Ovastasis LLC, H1 2020
- Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
- Female Contraception - Pipeline by Viramal Ltd, H1 2020
- Female Contraception - Pipeline by Yaso Therapeutics Inc, H1 2020
- Female Contraception - Pipeline by YourChoice Therapeutics Inc, H1 2020
- Female Contraception - Dormant Projects, H1 2020
- Female Contraception - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Female Contraception - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Female Contraception, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adare Pharmaceuticals Inc
- Agile Therapeutics Inc
- Dare Bioscience Inc
- Evestra Inc
- Exeltis Pharmaceuticals Holding SL
- Hervana Ltd
- Luye Pharma Group Ltd
- MedinCell SA
- Micron Biomedical Inc
- Mithra Pharmaceuticals SA
- Mucommune LLC
- Navad Life Sciences Pte Ltd
- Orion Biotechnology Canada Ltd
- Ovastasis LLC
- Teva Pharmaceutical Industries Ltd
- Viramal Ltd
- Yaso Therapeutics Inc
- YourChoice Therapeutics Inc
